Management of prostate cancer by targeting 3βHSD1 after enzalutamide and abiraterone treatment.
Mei Z, Yang T, Liu Y, Gao Y, Hou Z, Zhuang Q, He D, Zhang X, Tan Q, Zhu X, Qin Y, Chen X, Xu C, Bian C, Wang X, Wang C, Wu D, Huang S, Li Z.
Mei Z, et al. Among authors: bian c.
Cell Rep Med. 2022 May 17;3(5):100608. doi: 10.1016/j.xcrm.2022.100608. Epub 2022 Apr 20.
Cell Rep Med. 2022.
PMID: 35584629
Free PMC article.